A phase 1, randomized, placebo-controlled, single-and multiple-dose, double-blind study to evaluate the pharmacokinetics and safety of rimegepant orally disintegrating tablets 75 mg in healthy Chinese adults

被引：0
|
作者：
Li, Y. [1 ]
Bertz, R. [2 ]
Goodrich, R.
机构：
[1] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China
[2] Biohaven Pharmaceut, New Haven, CT USA
来源：
HEADACHE | 2022年 / 62卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
LB-P-19
引用
收藏
页码：922 / 922
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics and Safety of Single and Multiple Daily Dosing of 75-mg Rimegepant Orally Disintegrating Tablets in Healthy Chinese Adults: A Randomized Placebo-Controlled Trial
    Li, Yan
    Wang, Xinghe
    Ballesteros-Perez, Alex
    Bertz, Richard
    Lu, Zhihong
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (06): : 594 - 601
  • [2] A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants
    Bertz, Richard
    Bhardwaj, Rajinder
    Morris, Beth A. A.
    Ashbrenner, Eric
    Coric, Vladimir
    Croop, Robert
    CEPHALALGIA, 2023, 43 (06)
  • [3] Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
    Zhao, Qian
    Liu, Hongzhong
    Wang, Zhenlei
    Wang, Teng
    Cui, Cheng
    Wang, Huanhuan
    Li, Lili
    Zhong, Wen
    Jiang, Ji
    Dong, Kai
    Chen, Shuai
    Jin, Chunyan
    Hu, Pei
    ADVANCES IN THERAPY, 2023, 40 (07) : 3186 - 3198
  • [4] Randomized, double-blind, placebo-controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults
    Mitsui, Jun
    Matsukawa, Takashi
    Tanaka, Masaki
    Saito-Sato, Naoko
    Nakamoto, Fumiko Kusunoki
    Yasuda, Tsutomu
    Naruse, Hiroya
    Matsukawa, Miho Kawabe
    Ishiura, Hiroyuki
    Nagase, Midori
    Yamamoto, Yorihiro
    Kuzuyama, Haruko
    Wada, Ikue
    Ga, Toshio
    Yamazaki, Tsutomu
    Moritoyo, Takashi
    Tsuji, Shoji
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2022, 10 (01): : 14 - 24
  • [5] Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
    Qian Zhao
    Hongzhong Liu
    Zhenlei Wang
    Teng Wang
    Cheng Cui
    Huanhuan Wang
    Lili Li
    Wen Zhong
    Ji Jiang
    Kai Dong
    Shuai Chen
    Chunyan Jin
    Pei Hu
    Advances in Therapy, 2023, 40 : 3186 - 3198
  • [6] A Randomized, Single-Center, Double-Blind, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
    Matsuno, Kumi
    Tanaka, Shingo
    Hashimoto, Takamasa
    Nakamichi, Hiroyuki
    Kagawa, Tomoya
    Koumura, Emiko
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (11): : 1516 - 1524
  • [7] A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF OCR-002 IN HEALTHY VOLUNTEERS
    Jochelson, P.
    van de Wetering, J. L.
    Bornstein, J.
    Resler, M.
    Anderson, K.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S70 - S70
  • [8] A Double-blind, Placebo-controlled, Randomized, Single Ascending, and Multiple Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Dose Isomyosamine Capsules in Healthy Adult Subjects
    Brager, Jenna
    Chapman, Chris
    Dunn, Leonard
    Kaplin, Adam
    DRUG RESEARCH, 2023, 73 (02) : 95 - 104
  • [9] Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: a randomized, double-blind, placebo-controlled, phase 1 study
    Zhao, Xue
    Liu, Hongzhong
    Tian, Wei
    Fang, Ligang
    Yu, Mengyang
    Wu, Xiaofei
    Liu, Aijing
    Wan, Ruijie
    Li, Li
    Luo, Jinghui
    Li, Yuqiong
    Liu, Bo
    He, Yu
    Chen, Xiaowen
    Li, Yuan
    Xu, Donghong
    Wang, Hongyun
    Han, Xiaohong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [10] Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
    Yu, Shengyuan
    Guo, Aihong
    Wang, Zhen
    Liu, Jianguang
    Tan, Ge
    Yang, Qian
    Zhang, Mingjie
    Yibulaiyin, Hasiyeti
    Chen, Huisheng
    Zhang, Yongbo
    Croop, Robert
    Sun, Yanhui
    Liu, Yu
    Zhao, Qian
    Lu, Zhihong
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
12345